Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein

Craig G. Rogers, Gai Yan, Shan Zha, Mark L Gonzalgo, William B. Isaacs, Jun Luo, Angelo M. De Marzo, William G. Nelson, Christian P. Pavlovich

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Purpose: We assessed the feasibility of a novel urinary test for prostate cancer based on the presence of α methylacyl coenzyme A racemase (AMACR) protein in voided urine specimens obtained after prostate biopsy. Materials and Methods: Clean catch voided urine specimens were prospectively collected from 26 consecutive men immediately after transrectal ultrasound guided prostate biopsy for suspected malignancy. The presence of AMACR was evaluated in a blinded manner by Western blot analysis and correlated with biopsy results and patient clinical information. Results: AMACR was detected in the urine in 18 of 26 patients (69%). AMACR was detected in all 12 patients with biopsy confirmed adenocarcinoma of the prostate (100% sensitivity, 95% CI 75 to 100), in 5 of 12 with no evidence of cancer on biopsy (58% specificity, 95% CI 29 to 78) and in 1 of 2 (50%, 95% CI 3 to 80) with atypia on biopsy. Overall AMACR detection was associated with cancer status by prostate biopsy in 21 of 26 patients (86%). Conclusions: We report the feasibility of a novel, noninvasive, nonprostate specific antigen based molecular approach to detect prostate cancer in voided urine. To our knowledge this is the first report of AMACR protein detection in the urine of patients with prostate cancer. A screening test based on urinary AMACR may develop into a useful adjunct to serum prostate specific antigen and digital rectal examination for identifying men at increased risk for harboring prostate cancer despite negative biopsy. Such a test has potential application for stratifying patients into low and high risk groups for surveillance vs repeat biopsy.

Original languageEnglish (US)
Pages (from-to)1501-1503
Number of pages3
JournalJournal of Urology
Volume172
Issue number4 I
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Racemases and Epimerases
Urinalysis
Coenzymes
Prostatic Neoplasms
Biopsy
Proteins
Urine
Prostate
Digital Rectal Examination
Coenzyme A
Prostate-Specific Antigen
Neoplasms
Adenocarcinoma
Western Blotting
Antigens

Keywords

  • Prostate
  • Prostatic neoplasms
  • Tumor markers, biological
  • Urinalysis

ASJC Scopus subject areas

  • Urology

Cite this

Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein. / Rogers, Craig G.; Yan, Gai; Zha, Shan; Gonzalgo, Mark L; Isaacs, William B.; Luo, Jun; De Marzo, Angelo M.; Nelson, William G.; Pavlovich, Christian P.

In: Journal of Urology, Vol. 172, No. 4 I, 10.2004, p. 1501-1503.

Research output: Contribution to journalArticle

Rogers, CG, Yan, G, Zha, S, Gonzalgo, ML, Isaacs, WB, Luo, J, De Marzo, AM, Nelson, WG & Pavlovich, CP 2004, 'Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein', Journal of Urology, vol. 172, no. 4 I, pp. 1501-1503. https://doi.org/10.1097/01.ju.0000137659.53129.14
Rogers, Craig G. ; Yan, Gai ; Zha, Shan ; Gonzalgo, Mark L ; Isaacs, William B. ; Luo, Jun ; De Marzo, Angelo M. ; Nelson, William G. ; Pavlovich, Christian P. / Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein. In: Journal of Urology. 2004 ; Vol. 172, No. 4 I. pp. 1501-1503.
@article{7db52504e9204b1ebcce2a0dbbe8bcbe,
title = "Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein",
abstract = "Purpose: We assessed the feasibility of a novel urinary test for prostate cancer based on the presence of α methylacyl coenzyme A racemase (AMACR) protein in voided urine specimens obtained after prostate biopsy. Materials and Methods: Clean catch voided urine specimens were prospectively collected from 26 consecutive men immediately after transrectal ultrasound guided prostate biopsy for suspected malignancy. The presence of AMACR was evaluated in a blinded manner by Western blot analysis and correlated with biopsy results and patient clinical information. Results: AMACR was detected in the urine in 18 of 26 patients (69{\%}). AMACR was detected in all 12 patients with biopsy confirmed adenocarcinoma of the prostate (100{\%} sensitivity, 95{\%} CI 75 to 100), in 5 of 12 with no evidence of cancer on biopsy (58{\%} specificity, 95{\%} CI 29 to 78) and in 1 of 2 (50{\%}, 95{\%} CI 3 to 80) with atypia on biopsy. Overall AMACR detection was associated with cancer status by prostate biopsy in 21 of 26 patients (86{\%}). Conclusions: We report the feasibility of a novel, noninvasive, nonprostate specific antigen based molecular approach to detect prostate cancer in voided urine. To our knowledge this is the first report of AMACR protein detection in the urine of patients with prostate cancer. A screening test based on urinary AMACR may develop into a useful adjunct to serum prostate specific antigen and digital rectal examination for identifying men at increased risk for harboring prostate cancer despite negative biopsy. Such a test has potential application for stratifying patients into low and high risk groups for surveillance vs repeat biopsy.",
keywords = "Prostate, Prostatic neoplasms, Tumor markers, biological, Urinalysis",
author = "Rogers, {Craig G.} and Gai Yan and Shan Zha and Gonzalgo, {Mark L} and Isaacs, {William B.} and Jun Luo and {De Marzo}, {Angelo M.} and Nelson, {William G.} and Pavlovich, {Christian P.}",
year = "2004",
month = "10",
doi = "10.1097/01.ju.0000137659.53129.14",
language = "English (US)",
volume = "172",
pages = "1501--1503",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 I",

}

TY - JOUR

T1 - Prostate cancer detection on urinalysis for α methylacyl coenzyme a racemase protein

AU - Rogers, Craig G.

AU - Yan, Gai

AU - Zha, Shan

AU - Gonzalgo, Mark L

AU - Isaacs, William B.

AU - Luo, Jun

AU - De Marzo, Angelo M.

AU - Nelson, William G.

AU - Pavlovich, Christian P.

PY - 2004/10

Y1 - 2004/10

N2 - Purpose: We assessed the feasibility of a novel urinary test for prostate cancer based on the presence of α methylacyl coenzyme A racemase (AMACR) protein in voided urine specimens obtained after prostate biopsy. Materials and Methods: Clean catch voided urine specimens were prospectively collected from 26 consecutive men immediately after transrectal ultrasound guided prostate biopsy for suspected malignancy. The presence of AMACR was evaluated in a blinded manner by Western blot analysis and correlated with biopsy results and patient clinical information. Results: AMACR was detected in the urine in 18 of 26 patients (69%). AMACR was detected in all 12 patients with biopsy confirmed adenocarcinoma of the prostate (100% sensitivity, 95% CI 75 to 100), in 5 of 12 with no evidence of cancer on biopsy (58% specificity, 95% CI 29 to 78) and in 1 of 2 (50%, 95% CI 3 to 80) with atypia on biopsy. Overall AMACR detection was associated with cancer status by prostate biopsy in 21 of 26 patients (86%). Conclusions: We report the feasibility of a novel, noninvasive, nonprostate specific antigen based molecular approach to detect prostate cancer in voided urine. To our knowledge this is the first report of AMACR protein detection in the urine of patients with prostate cancer. A screening test based on urinary AMACR may develop into a useful adjunct to serum prostate specific antigen and digital rectal examination for identifying men at increased risk for harboring prostate cancer despite negative biopsy. Such a test has potential application for stratifying patients into low and high risk groups for surveillance vs repeat biopsy.

AB - Purpose: We assessed the feasibility of a novel urinary test for prostate cancer based on the presence of α methylacyl coenzyme A racemase (AMACR) protein in voided urine specimens obtained after prostate biopsy. Materials and Methods: Clean catch voided urine specimens were prospectively collected from 26 consecutive men immediately after transrectal ultrasound guided prostate biopsy for suspected malignancy. The presence of AMACR was evaluated in a blinded manner by Western blot analysis and correlated with biopsy results and patient clinical information. Results: AMACR was detected in the urine in 18 of 26 patients (69%). AMACR was detected in all 12 patients with biopsy confirmed adenocarcinoma of the prostate (100% sensitivity, 95% CI 75 to 100), in 5 of 12 with no evidence of cancer on biopsy (58% specificity, 95% CI 29 to 78) and in 1 of 2 (50%, 95% CI 3 to 80) with atypia on biopsy. Overall AMACR detection was associated with cancer status by prostate biopsy in 21 of 26 patients (86%). Conclusions: We report the feasibility of a novel, noninvasive, nonprostate specific antigen based molecular approach to detect prostate cancer in voided urine. To our knowledge this is the first report of AMACR protein detection in the urine of patients with prostate cancer. A screening test based on urinary AMACR may develop into a useful adjunct to serum prostate specific antigen and digital rectal examination for identifying men at increased risk for harboring prostate cancer despite negative biopsy. Such a test has potential application for stratifying patients into low and high risk groups for surveillance vs repeat biopsy.

KW - Prostate

KW - Prostatic neoplasms

KW - Tumor markers, biological

KW - Urinalysis

UR - http://www.scopus.com/inward/record.url?scp=4544337635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544337635&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000137659.53129.14

DO - 10.1097/01.ju.0000137659.53129.14

M3 - Article

VL - 172

SP - 1501

EP - 1503

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 I

ER -